Evolent Health Inc (NYSE:EVH) – Analysts at Leerink Swann issued their Q1 2018 earnings per share estimates for Evolent Health in a report released on Monday. Leerink Swann analyst D. Larsen expects that the technology company will earn ($0.02) per share for the quarter. Leerink Swann has a “Buy” rating and a $25.00 price target on the stock. Leerink Swann also issued estimates for Evolent Health’s Q2 2018 earnings at ($0.01) EPS, Q3 2018 earnings at ($0.01) EPS, Q4 2018 earnings at ($0.01) EPS, FY2018 earnings at ($0.05) EPS and FY2019 earnings at $0.17 EPS.
A number of other analysts also recently issued reports on EVH. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Evolent Health in a report on Friday, August 18th. Jefferies Group reaffirmed a “buy” rating and set a $28.00 price objective on shares of Evolent Health in a report on Wednesday, September 6th. KeyCorp initiated coverage on shares of Evolent Health in a report on Tuesday, September 19th. They set an “overweight” rating and a $23.00 price objective for the company. SunTrust Banks reaffirmed a “buy” rating and set a $30.00 price objective on shares of Evolent Health in a report on Wednesday, September 20th. Finally, Robert W. Baird reaffirmed an “outperform” rating and set a $25.00 price objective (down from $35.00) on shares of Evolent Health in a report on Tuesday, September 26th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, one has assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $28.00.
Evolent Health (NYSE EVH) traded down $0.10 during midday trading on Thursday, hitting $12.90. 1,177,000 shares of the stock were exchanged, compared to its average volume of 1,267,563. Evolent Health has a 52 week low of $10.30 and a 52 week high of $27.50. The company has a quick ratio of 3.34, a current ratio of 3.34 and a debt-to-equity ratio of 0.11.
Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Thursday, November 2nd. The technology company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.04. Evolent Health had a negative net margin of 15.86% and a negative return on equity of 5.05%. The firm had revenue of $107.90 million during the quarter, compared to the consensus estimate of $104.49 million. During the same period last year, the firm earned ($0.26) EPS. The business’s quarterly revenue was up 79.2% compared to the same quarter last year.
A number of large investors have recently modified their holdings of EVH. FMR LLC raised its position in Evolent Health by 117.7% in the 2nd quarter. FMR LLC now owns 9,864,775 shares of the technology company’s stock worth $250,073,000 after purchasing an additional 5,333,252 shares during the period. JPMorgan Chase & Co. raised its position in Evolent Health by 37.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 7,465,019 shares of the technology company’s stock worth $136,236,000 after purchasing an additional 2,026,893 shares during the period. Vanguard Group Inc. raised its position in Evolent Health by 48.9% in the 2nd quarter. Vanguard Group Inc. now owns 3,769,869 shares of the technology company’s stock worth $95,566,000 after purchasing an additional 1,237,941 shares during the period. Eagle Asset Management Inc. purchased a new position in Evolent Health in the 2nd quarter worth $27,577,000. Finally, Kornitzer Capital Management Inc. KS purchased a new position in Evolent Health in the 3rd quarter worth $14,258,000. Institutional investors own 95.38% of the company’s stock.
About Evolent Health
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.